依托泊苷
聚乙二醇非格司亭
医学
白细胞清除术
普乐沙福
多发性骨髓瘤
川地34
淋巴瘤
内科学
自体干细胞移植
阿糖胞苷
化疗
胃肠病学
干细胞
肿瘤科
外科
菲格拉斯汀
粒细胞集落刺激因子
生物
炎症
CXCR4型
遗传学
趋化因子
作者
Peipei Ye,Renzhi Pei,Jiaying Lian,Dong Chen,Shuangyue Li,Yan Cheng,Fenglin Li,Jiaojiao Yuan,Chen Yao,Yunlong Lu
出处
期刊:Cytotherapy
[Elsevier]
日期:2023-08-01
卷期号:25 (8): 885-890
标识
DOI:10.1016/j.jcyt.2023.04.014
摘要
Background aims An optimal strategy for mobilizing hematopoietic stem cells in poorly mobilizing patients with multiple myeloma (MM) and lymphoma has not yet been determined. Methods We retrospectively analyzed the efficacy and safety of etoposide combined with cytarabine (etoposide 75 mg/m2, daily d1∼2; Ara-C 300 mg/m2, every 12 h d1∼2), plus pegfilgrastim (6 mg d6) in 32 patients with MM or lymphoma, among whom 53.1% were defined as “proven poor mobilizers.” Results This approach resulted in adequate mobilization (≥2.0 × 106 CD34+ cells/kg) in 93.8% of patients and optimal mobilization (≥5.0 × 106 CD34+ cells/kg) in 71.9% of patients. A total of 100% of patients with MM reached at least 5 × 106 CD34+ cells/kg collected, the amount required for double autologous stem cell transplant. In total, 88.2% of patients with lymphoma reached at least 2 × 106 CD34+ cells/kg collected, the amount required for a single autologous stem cell transplant. This was achieved with a single leukapheresis in 78.1% of cases. A median peak number of 42.0/μL circulating CD34+ cells and a median number of blood CD34+ cells counts in 6.7 × 106/L were collected among 30 successful mobilizers. Approximately 6.3% of patients required plerixafor rescue, which was successful. Nine (28.1%) of the 32 patients suffered grade 2∼3 infections, and 50% required platelet transfusions. Conclusions We conclude that chemo-mobilization with etoposide, Ara-C and pegfilgrastim in poorly mobilizing patients with MM or lymphoma is very effective and has acceptable toxicity.
科研通智能强力驱动
Strongly Powered by AbleSci AI